loading
Ionis Pharmaceuticals Inc stock is traded at $31.68, with a volume of 557.58K. It is down -2.63% in the last 24 hours and down -9.15% over the past month. Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
See More
Previous Close:
$32.63
Open:
$32.56
24h Volume:
557.58K
Relative Volume:
0.38
Market Cap:
$5.15B
Revenue:
$803.07M
Net Income/Loss:
$-358.81M
P/E Ratio:
-12.98
EPS:
-2.44
Net Cash Flow:
$-374.21M
1W Performance:
-0.40%
1M Performance:
-9.15%
6M Performance:
-32.13%
1Y Performance:
-35.87%
1-Day Range:
Value
$31.75
$32.73
1-Week Range:
Value
$31.03
$33.62
52-Week Range:
Value
$31.03
$52.34

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name
Name
Ionis Pharmaceuticals Inc
Name
Phone
(760) 931-9200
Name
Address
2855 GAZELLE COURT, CARLSBAD, CA
Name
Employee
927
Name
Twitter
@ionispharma
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
IONS's Discussions on Twitter

Compare IONS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IONS
Ionis Pharmaceuticals Inc
31.79 5.15B 803.07M -358.81M -374.21M -2.44
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
473.86 123.91B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
716.63 78.94B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
651.92 39.98B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
275.00 35.89B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
118.86 28.75B 3.30B -501.07M 1.03B -2.1146

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-02-24 Downgrade BMO Capital Markets Outperform → Market Perform
Jul-24-24 Upgrade Leerink Partners Market Perform → Outperform
Jul-16-24 Resumed Jefferies Buy
Jun-14-24 Upgrade Bernstein Underperform → Mkt Perform
Apr-10-24 Upgrade Wolfe Research Peer Perform → Outperform
Jan-02-24 Upgrade BofA Securities Neutral → Buy
Oct-23-23 Upgrade BofA Securities Underperform → Neutral
Sep-29-23 Initiated Raymond James Strong Buy
Jul-31-23 Upgrade Citigroup Neutral → Buy
Jun-07-23 Resumed Piper Sandler Overweight
May-04-23 Upgrade Citigroup Sell → Neutral
Mar-21-23 Initiated Bernstein Underperform
Dec-21-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-09-22 Resumed Morgan Stanley Overweight
Jul-18-22 Resumed Oppenheimer Outperform
Mar-31-22 Resumed Piper Sandler Overweight
Mar-01-22 Initiated Citigroup Sell
Mar-01-22 Initiated Guggenheim Buy
Feb-01-22 Downgrade BofA Securities Buy → Underperform
Dec-14-21 Upgrade William Blair Mkt Perform → Outperform
May-07-21 Upgrade UBS Sell → Neutral
Mar-01-21 Upgrade Barclays Underweight → Equal Weight
Dec-16-20 Initiated UBS Sell
Dec-15-20 Upgrade Cowen Market Perform → Outperform
Sep-14-20 Resumed JP Morgan Neutral
Sep-02-20 Initiated The Benchmark Company Hold
Jun-01-20 Resumed Oppenheimer Outperform
May-13-20 Initiated RBC Capital Mkts Outperform
Mar-05-20 Initiated Citigroup Buy
Dec-13-19 Initiated Oppenheimer Outperform
Nov-13-19 Initiated BofA/Merrill Buy
Nov-07-19 Downgrade Morgan Stanley Equal-Weight → Underweight
Sep-10-19 Upgrade Bernstein Mkt Perform → Outperform
Aug-08-18 Reiterated Stifel Hold
Aug-07-18 Reiterated Stifel Hold
May-08-18 Downgrade Evercore ISI Outperform → In-line
Oct-06-17 Resumed Goldman Sell
Aug-17-17 Initiated Evercore ISI Outperform
Aug-09-17 Reiterated Stifel Hold
Mar-10-17 Downgrade Goldman Neutral → Sell
Dec-28-16 Reiterated BMO Capital Markets Outperform
Dec-27-16 Reiterated Leerink Partners Mkt Perform
View All

Ionis Pharmaceuticals Inc Stock (IONS) Latest News

pulisher
07:13 AM

Ionis Pharmaceuticals EVP sells $194,939 in stock - MSN

07:13 AM
pulisher
Feb 06, 2025

Insider Sell: Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus.com

Feb 06, 2025
pulisher
Feb 06, 2025

Insider Sell: Patrick O'neil Sells Shares of Ionis Pharmaceutica - GuruFocus.com

Feb 06, 2025
pulisher
Feb 06, 2025

Ionis Pharmaceuticals CEO sells $1.23 million in stock - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

Ionis Pharmaceuticals CEO sells $1.23 million in stock By Investing.com - Investing.com Canada

Feb 06, 2025
pulisher
Feb 06, 2025

EVP CLO & General Counsel O'Neil Patrick R. sold $194,939 worth of shares (6,165 units at $31.62), decreasing direct ownership by 10% to 57,452 units (SEC Form 4) - Quantisnow

Feb 06, 2025
pulisher
Feb 06, 2025

Elizabeth L. Hougen Sells 1,523 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $44,167.77 in Stock - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

Brett P. Monia Sells 13,242 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

DAVENPORT & Co LLC Cuts Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Feb 06, 2025
pulisher
Feb 05, 2025

Hereditary Transthyretin Amyloidosis (hATTR) Market Growth Projections 2023-2032: DelveInsight Analysis | Eidos, Corino, Prothena, Ionis Pharma, AstraZeneca, Novo Nordisk - Barchart

Feb 05, 2025
pulisher
Feb 05, 2025

Amyotrophic Lateral Sclerosis Market Expected to Experience Major Growth by 2034, According to DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma - Barchart

Feb 05, 2025
pulisher
Feb 05, 2025

Hereditary Transthyretin Amyloidosis (hATTR) Market Growth - openPR

Feb 05, 2025
pulisher
Feb 05, 2025

Biogen wins U.S. EU review for higher dose version of SMA drug marketed with Ionis - MSN

Feb 05, 2025
pulisher
Feb 05, 2025

Ionis to hold fourth quarter and full year 2024 financial results webcast - BioSpace

Feb 05, 2025
pulisher
Feb 04, 2025

Angioedema Pipeline 2024: Therapies Under Investigation, - openPR

Feb 04, 2025
pulisher
Feb 03, 2025

Insider Sell Alert: C Bennett Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus.com

Feb 03, 2025
pulisher
Feb 03, 2025

Insider Sell Alert: Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus.com

Feb 03, 2025
pulisher
Feb 03, 2025

Insider Sell: Elizabeth Hougen Sells Shares of Ionis Pharmaceuti - GuruFocus.com

Feb 03, 2025
pulisher
Feb 03, 2025

Insider Sell Alert: Eugene Schneider Sells Shares of Ionis Pharm - GuruFocus.com

Feb 03, 2025
pulisher
Feb 03, 2025

EVP Research Swayze Eric sold $44,162 worth of shares (1,367 units at $32.31) and was granted 3,714 shares, increasing direct ownership by 5% to 48,017 units (SEC Form 4) - Quantisnow

Feb 03, 2025
pulisher
Feb 03, 2025

EVP, Chf Clinical Develop Ofcr Schneider Eugene was granted 4,032 shares and sold $47,780 worth of shares (1,484 units at $32.20), increasing direct ownership by 4% to 61,056 units (SEC Form 4) - Quantisnow

Feb 03, 2025
pulisher
Feb 03, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) Reaches New 12-Month LowHere's Why - MarketBeat

Feb 03, 2025
pulisher
Feb 02, 2025

SG Americas Securities LLC Boosts Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat

Feb 02, 2025
pulisher
Feb 02, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Feb 02, 2025
pulisher
Feb 01, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap DownTime to Sell? - MarketBeat

Feb 01, 2025
pulisher
Feb 01, 2025

Ionis announces European licensing agreement with Otsuka for don - GuruFocus.com

Feb 01, 2025
pulisher
Feb 01, 2025

10 Promising Biotech Stocks to Invest in (February 2025) - Securities.io

Feb 01, 2025
pulisher
Jan 31, 2025

Ionis Pharmaceuticals Says Data Readout From Pelacarsen Study Is Delayed -January 31, 2025 at 01:17 pm EST - Marketscreener.com

Jan 31, 2025
pulisher
Jan 31, 2025

Ionis stock slips as Novartis delays heart drug trial (NVS) - Seeking Alpha

Jan 31, 2025
pulisher
Jan 29, 2025

Familial Chylomicronemia Syndrome FDA Approvals, Clinical - openPR

Jan 29, 2025
pulisher
Jan 27, 2025

September 19th Options Now Available For Ionis Pharmaceuticals - Nasdaq

Jan 27, 2025
pulisher
Jan 26, 2025

Ionis Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 24, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) Shares Up 7%Time to Buy? - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug - Yahoo Finance

Jan 24, 2025
pulisher
Jan 24, 2025

What is Leerink Partnrs’ Forecast for IONS FY2024 Earnings? - Defense World

Jan 24, 2025
pulisher
Jan 23, 2025

Spinocerebellar Ataxias Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart

Jan 23, 2025
pulisher
Jan 23, 2025

70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight - Yahoo Finance

Jan 23, 2025
pulisher
Jan 23, 2025

Ionis stock rises on FDA, EMA nod for SMA drug dose increase - MSN

Jan 23, 2025
pulisher
Jan 23, 2025

William Blair Brokers Increase Earnings Estimates for IONS - MarketBeat

Jan 23, 2025
pulisher
Jan 23, 2025

Biogen/ Ionis Spinraza being reviewed for higher dose (BIIB) - Seeking Alpha

Jan 23, 2025
pulisher
Jan 23, 2025

Leerink Partnrs Has Negative Outlook of IONS FY2024 Earnings - MarketBeat

Jan 23, 2025
pulisher
Jan 23, 2025

Ionis Pharmaceuticals Insiders Sold US$3.2m Of Shares Suggesting Hesitancy - Simply Wall St

Jan 23, 2025
pulisher
Jan 23, 2025

Transthyretin Amyloid Cardiomyopathy Treatment Market - openPR

Jan 23, 2025
pulisher
Jan 21, 2025

Assenagon Asset Management S.A. Raises Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat

Jan 21, 2025
pulisher
Jan 21, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Position Boosted by Assenagon Asset Management S.A. - Defense World

Jan 21, 2025
pulisher
Jan 19, 2025

Ionis Pharmaceuticals EVP sells $241,628 in stock - MSN

Jan 19, 2025
pulisher
Jan 19, 2025

Ionis Pharmaceuticals EVP Brian Birchler sells $176,580 in stock - MSN

Jan 19, 2025
pulisher
Jan 19, 2025

Ionis Pharmaceuticals exec sells $144,861 in stock - MSN

Jan 19, 2025
pulisher
Jan 19, 2025

Ionis Pharmaceuticals EVP Eric Swayze sells $235,678 in stock - MSN

Jan 19, 2025

Ionis Pharmaceuticals Inc Stock (IONS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Ionis Pharmaceuticals Inc Stock (IONS) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Monia Brett P
Chief Executive Officer
Feb 04 '25
Sale
31.65
38,843
1,229,463
180,683
$80.51
price down icon 0.51%
$20.05
price down icon 2.99%
$347.95
price down icon 1.50%
$4.70
price down icon 6.75%
biotechnology ONC
$223.12
price down icon 2.61%
$118.75
price down icon 0.97%
Cap:     |  Volume (24h):